Twist Bioscience Presents White Paper on Sizing the Future DNA Data Storage Market | New
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 2, 2022–
Twist Bioscience Corporation (NASDAQ: TWST), a company that enables customers to succeed through its high-quality synthetic DNA offering using its silicon platform, today shared a new white paper from Furthur Market Research 1 highlighting the dramatic need for new enterprise storage technologies that can be more cost-effectively deployed at scale with minimal power consumption, such as DNA data storage.
“We estimated the maximum production capacities of current storage technologies (hard disk drive (HDD), solid state drive (SSD), tape) and concluded that the potential demand at growth rates above 25% per year would exceed available supply from all media,” said John Monroe, founder of Furthur Market Research and lead author of the paper. “It is important to note that beyond 2025, new DNA storage technologies , optical, and perhaps other ventures will be needed to cost-effectively and reliably preserve the priceless artifacts of our personal, corporate, and cultural history.”
Storage capacity today, not available tomorrow: potential shortfall area
To date, the company’s storage capacity continues to be available, but data shows that at current and projected growth rates, there will likely be areas of potential shortfall where planned storage capacity cannot not meet storage demand.
The new whitepaper confirms that in 2019, 2020, and 2021, enterprise petabyte shipments accelerated and grew by 35%, 33.6%, and 48.3%, respectively. Estimates show that:
- Assuming a 35% annual growth rate in enterprise storage demand, in 2030 the potential shortfall area could be 7.9 million petabytes (7.9 ZB).
- Assuming a 45% annual growth rate, the potential shortfall area in 2030 could exceed 25 million petabytes (25 ZB).
The volume of archive (cold) data could represent approximately 75% of the installed base of enterprise data, and not be deleted
Several industry interviews with industry executives responsible for storage infrastructures over 100 petabytes in various markets have stated that their data retention periods are “indefinite”. The author notes that to date, we have seen little to no inclination of any kind at any company to delete data, and there is no reason to believe this trend will change.
- Approximately 75% of the active installed base of enterprise storage could be “cold”, containing mostly “Just In Case” (JIC) or “Write Once Read Never” (WORN) data.
- Cold storage data may never be accessed at all, and in most cases it will never be deleted
“DNA delivers on the promise of delivering the three magic solutions to storage: ultra-high density, reasonable cost, and durability. We expect new media to be needed to meet the more than $7 billion in unmet storage demand predicted in the coming years, and we remain at the forefront of innovation in this market with a view to ‘to introduce the first commercial DNA data storage solution in the near future,’ commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
Increasing Power Requirements for Current Storage Solutions: Sustainability Considerations
The report notes that new storage technologies need to be more durable as the global appetite for data grows.
Dr. Leproust continued: “Today, the vast majority of business data is stored on hard drives, which consume a lot of energy. As we prepare for the rapid growth in storage demand, any new medium must reduce power consumption by one to two orders of magnitude. DNA is about to do just that.
To read the full storage white paper, go to: https://www.twistbioscience.com/resources/white-paper/escalating-challenge-preserving-enterprise-data.
About Twist Bioscience
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is proprietary technology that pioneers a new method of making synthetic DNA by “writing” DNA onto a silicon chip. Twist leverages its unique technology to manufacture a wide range of synthetic DNA products, including synthetic genes, tools for Next Generation Sequencing (NGS) preparation, and antibody libraries for discovery and drug development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologic drug discovery. Twist manufactures products for many industries including healthcare, industrial chemicals, agriculture and academic research.
follow us on Twitter | Facebook | LinkedIn | Youtube
Legal notice regarding forward-looking statements
This press release contains forward-looking statements. All statements other than statements of historical fact contained herein, including but not limited to projections of unmet demand for data storage, are forward-looking statements reflecting the current beliefs and expectations of management, made in accordance with the safe harbor provisions of the Private Securities Litigation Reform. Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of Twist Bioscience to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; the risks and uncertainties of rapidly changing technologies and intense competition in synthetic biology could render the products that Twist Bioscience develops obsolete or uncompetitive; retention of employees of acquired companies and Twist Bioscience’s ability to successfully integrate acquired companies and obtain anticipated benefits, risks of third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate patents or Twist Bioscience’s proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business generally, see Twist Bioscience’s risk factors stated in Twist Bioscience’s quarterly report. on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2022 and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
1 White paper jointly sponsored by Fujifilm and Twist Bioscience.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220802005500/en/
CONTACT: Angela Bitting
SVP, Corporate Affairs
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH GENETIC RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Twist Bioscience Corporation
Copyright BusinessWire 2022.
PUBLISHED: 02/08/2022 08:01 / DISK: 02/08/2022 08:03